Teva's New Copaxone Formulation For MS Patients Approved By FDA

The U.S. Food and Drug Administration (FDA) has approved Teva’s supplemental new drug application (sNDA) for a new formulation for Copaxone. Copaxone is now available in 40mg/mL in a three-times-a-week dosage.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news